Gene Therapy for Liver Cancer
Rockville, Md --GenVec has begun a phase I study of its in vivo gene-based product, AdgvCD. 10, in 18 patients with liver metastases of colectoral cancer . An advenovirus vector modified to carry the cytosine deaminase gene will be administered directly into the hepatic tumor. The gene expresses an enzyme that converts 5-fluorocytosine,an oral anti-fungal agent , into the potent anticancer agent 5-fluorouracil.. The conversion occurs only at the site of gene expression, the company said.
Rockville, Md --GenVec has begun a phase I study of its in vivogene-based product, AdgvCD. 10, in 18 patients with liver metastasesof colectoral cancer . An advenovirus vector modified to carrythe cytosine deaminase gene will be administered directly intothe hepatic tumor. The gene expresses an enzyme that converts5-fluorocytosine,an oral anti-fungal agent , into the potent anticanceragent 5-fluorouracil.. The conversion occurs only at the siteof gene expression, the company said.
News and Expert Insights in Hemophilia Gene Therapy for Bleeding Disorders Awareness Month 2025
March 9th 2025In observance of Bleeding Disorders Awareness Month, held annually in March, catch up on some of the latest news and expert insights in gene therapy for hemophilia, which is among the most common of these disorders.
